MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Inflammation and Regeneration is a prominent open-access journal published by BMC, focused on the discerning fields of immunology, cell biology, and regenerative medicine. Since its establishment in 2016, the journal has provided a platform for the dissemination of high-quality research, contributing significantly to the advancement of knowledge in inflammation processes and regenerative therapies. With a remarkable impact reflected in its Q1 quartile rankings in Cell Biology and Immunology for 2023, Inflammation and Regeneration stands out as a leading resource for researchers and practitioners. The journal's commitment to open access ensures that critical findings are readily available to a global audience, fostering collaboration and innovation in the scientific community. With a Scopus ranking that places it in the top 20% of its categories, Inflammation and Regeneration serves as an essential reference for those seeking to stay at the forefront of immunological research and its applications.

DERMATOLOGY, an esteemed journal published by KARGER, is a vital resource in the field of dermatological research and clinical practice. Established in 1893, with its comprehensive coverage extending to 2024, this journal has earned its place as a leading publication, holding a prestigious Q1 quartile ranking in Dermatology and ranking 15th out of 142 in the Scopus Medicine - Dermatology category, reflecting its 89th percentile standing within the discipline. The journal aims to disseminate innovative research findings, critical reviews, and clinical studies that advance the understanding of skin disorders and their treatments. While primarily available through institutional subscriptions, DERMATOLOGY remains committed to enhancing accessibility and fostering international collaboration among researchers, professionals, and students in the dermatological community. Its rigorous peer-review process guarantees the highest quality of published works, making it an essential reference for those dedicated to advancing dermatological science and improving patient care.